Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel enzymatic resolution route for high-purity Alzheimer's intermediate. Reduces cost and improves scalability for pharma manufacturing.
Patent CN102154377B reveals ScCR enzyme for asymmetric reduction. Enables cost-effective manufacturing of pharmaceutical intermediates with self-regenerating cofactors.
Patent CN112458143B reveals a novel whole-cell catalytic route for Ezetimibe intermediates. Discover how this green biocatalysis technology reduces costs and ensures supply chain stability.
Patent CN102154384A reveals efficient recombinant E. coli method yielding >26g/L with >99% ee, offering significant cost and supply chain advantages.
Patent CN107858384A reveals a fusion enzyme method for L-tert-leucine. Offers high purity, thermal stability, and reusable biocatalysts for cost-effective pharmaceutical intermediate manufacturing.
Patent CN119823958B reveals high-yield enzyme route for Clopidogrel intermediate offering cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN112852771A details enzymatic synthesis of chiral amino alcohols using imine reductase, offering high stereoselectivity and mild conditions for pharmaceutical manufacturing.
Patent CN115820584A reveals high-efficiency mutants for L-phenylglycine and L-2-aminobutyric acid synthesis, offering cost reduction and supply reliability.
Patent CN1554646A details a novel chemo-enzymatic route for lactam production. This method offers significant cost reduction in fine chemical manufacturing through high regioselectivity and simplified downstream processing.
Patent CN116731988B reveals high-purity pharmaceutical intermediates synthesis via engineered ketoreductase, ensuring supply chain reliability and cost reduction.
Patent CN102174422B reveals high-activity lipase for chiral resolution. Offers solvent stability and cost reduction in biocatalysis manufacturing for pharma intermediates.
Patent CN115404249A reveals a novel enzymatic route for (S)-nicotine intermediates. Discover cost-effective biocatalysis solutions for scalable pharmaceutical manufacturing.
Patent CN101535467B discloses a novel biocatalytic route for chiral hydroxy acids using Fusarium proliferatum ECU2002, offering high optical purity and scalable manufacturing solutions.
Novel aminotransferase mutant enables 99% ee sitagliptin intermediate. Robust DMSO tolerance ensures cost reduction in pharma manufacturing.
Novel nitrilase enables efficient production of chiral intermediates for clopidogrel with reduced environmental impact and scalable supply chain solutions.
Patent CN112359079B reveals a novel enzymatic route for Imatamine. Achieve high purity and cost reduction in API manufacturing with our scalable green chemistry solutions.
Patent CN102586384B reveals a novel deracemization method for D-amino acids using Alcaligenes faecalis, offering high optical purity and simplified downstream processing for pharmaceutical supply chains.
Patent CN114686465A reveals a hydrolase method for (R)-3-(carbamoylmethyl)-5-methylhexanoic acid, offering green, high-yield production for reliable supply chains.
Patent CN106191151B reveals a novel biotransformation route for high-purity D-lysine and 5-aminovaleric acid co-production, offering significant supply chain and cost advantages for global manufacturers.
Patent CN108570460B discloses novel SDR mutants enabling high-selectivity biocatalytic reduction of acetophenone derivatives, offering a greener alternative for pharmaceutical intermediate manufacturing.